TY - JOUR
T1 - Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival
T2 - A Phase I/II Controlled, Randomized Study
AU - Parmar, Simrit
AU - Rondon, Gabriela
AU - de Lima, Marcos
AU - Thall, Peter
AU - Bassett, Ronald
AU - Anderlini, Paolo
AU - Kebriaei, Partow
AU - Khouri, Issa
AU - Ganesan, Prasanth
AU - Champlin, Richard
AU - Giralt, Sergio
PY - 2013/3
Y1 - 2013/3
N2 - Dose intensity is important for disease control in patients undergoing allogeneic stem cell transplantation. We conducted a phase I/II controlled, adoptive, randomized study to determine the optimal dosing schedule of i.v. busulfan. Patients aged ≤75 years with advanced hematologic malignancies with human leukocyte antigen-compatible donor were eligible. All patients received fludarabine at 30 mg/m2/d for 4 days, and busulfan was administered in different doses in oral or i.v. formulations. As determined by the phase I trial, i.v. busulfan at a dose of 11.2 mg/kg/d was used for the phase II expansion cohort. Altogether, 80 patients with a median age of 56 years were enrolled. Forty percent had active disease at the time of transplantation. Engraftment occurred in 91%, and a complete response was achieved in 79% of patients posttransplantation. At a median follow-up of 91 months in the surviving patients, the outcomes for i.v. busulfan dose of 11.2 mg/kg/d versus other doses were as follows: nonrelapse mortality, 34% versus 23% (P = .4); cumulative incidence of relapse, 43% versus 68% (P = .02); relapse-free survival, 25% versus 9% (P = .017); and overall survival, 27% versus 9% (P = .02). We conclude that optimizing i.v. busulfan dose intensity in the preparative regimen may overcome disease-associated poor prognostic factors.
AB - Dose intensity is important for disease control in patients undergoing allogeneic stem cell transplantation. We conducted a phase I/II controlled, adoptive, randomized study to determine the optimal dosing schedule of i.v. busulfan. Patients aged ≤75 years with advanced hematologic malignancies with human leukocyte antigen-compatible donor were eligible. All patients received fludarabine at 30 mg/m2/d for 4 days, and busulfan was administered in different doses in oral or i.v. formulations. As determined by the phase I trial, i.v. busulfan at a dose of 11.2 mg/kg/d was used for the phase II expansion cohort. Altogether, 80 patients with a median age of 56 years were enrolled. Forty percent had active disease at the time of transplantation. Engraftment occurred in 91%, and a complete response was achieved in 79% of patients posttransplantation. At a median follow-up of 91 months in the surviving patients, the outcomes for i.v. busulfan dose of 11.2 mg/kg/d versus other doses were as follows: nonrelapse mortality, 34% versus 23% (P = .4); cumulative incidence of relapse, 43% versus 68% (P = .02); relapse-free survival, 25% versus 9% (P = .017); and overall survival, 27% versus 9% (P = .02). We conclude that optimizing i.v. busulfan dose intensity in the preparative regimen may overcome disease-associated poor prognostic factors.
KW - Intravenous busulfan
KW - Reduced-intensity transplant
KW - Relapsed/refractory leukemia
UR - http://www.scopus.com/inward/record.url?scp=84873603965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873603965&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2012.12.001
DO - 10.1016/j.bbmt.2012.12.001
M3 - Article
C2 - 23220013
AN - SCOPUS:84873603965
SN - 1083-8791
VL - 19
SP - 474
EP - 480
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 3
ER -